Cited by 326Cancer Immunotherapy and BiomarkersTryptophan and brain disordersBacterial Cancer Therapy

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

Open access

Triplett, Todd A, Garrison, Kendra C, Marshall, Nicholas, Donkor, Moses, Blazeck, John, Lamb, Candice, Qerqez, Ahlam, Dekker, Joseph D, Tanno, Yuri, Lu, Wei-Cheng, Karamitros, Christos S, Ford, Kyle, Tan, Bing, Zhang, Xiaoyan M, McGovern, Karen, Coma, Silvia, Kumada, Yoichi, Yamany, Mena S, Sentandreu, Enrique, Fromm, George, Tiziani, Stefano, Schreiber, Taylor H, Manfredi, Mark, Ehrlich, Lauren I R, Stone, Everett, Georgiou, George·2018·Nature Biotechnology

DOI 10.1038/nbt.4180PMC PMC6078800

Open this paper in CoChat — free account

Abstract

Increased tryptophan (Trp) catabolism in the tumor microenvironment (TME) can mediate immune suppression by upregulation of interferon (IFN)-γ-inducible indoleamine 2,3-dioxygenase (IDO1) and/or ectopic expression of the predominantly liver-restricted enzyme tryptophan 2,3-dioxygenase (TDO). Whether these effects are due to Trp depletion in the TME or mediated by the accumulation of the IDO1 and/or TDO (hereafter referred to as IDO1/TDO) product kynurenine (Kyn) remains controversial. Here we show that administration of a pharmacologically optimized enzyme (PEGylated kynureninase; hereafter referred to as PEG-KYNase) that degrades Kyn into immunologically inert, nontoxic and readily cleared metabolites inhibits tumor growth. Enzyme treatment was associated with a marked increase in the tumor infiltration and proliferation of polyfunctional CD8+ lymphocytes. We show that PEG-KYNase administration had substantial therapeutic effects when combined with approved checkpoint inhibitors or with a cancer vaccine for the treatment of large B16-F10 melanoma, 4T1 breast carcinoma or CT26 colon carcinoma tumors. PEG-KYNase mediated prolonged depletion of Kyn in the TME and reversed the modulatory effects of IDO1/TDO upregulation in the TME.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.4180

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Over-production of Proteins inEscherichia coli: Mutant Hosts that Allow Synthesis of some Membrane Proteins and Globular Proteins at High Levels
Miroux, B., & Walker, J. E. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0399 · Cited by 1,964
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,674
Self-citation
Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health
Cervenka, I., Agudelo, L. Z., & Ruas, J. L. (2017) · Science · doi:10.1126/science.aaf9794 · Cited by 1,382
Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,093
Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells
Terness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 965
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 953
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & den Eynde, B. J. V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 725

Show all 40 references

Sorted by citations

Items 201–300 of 326

The Biocatalysis in Cancer Therapy
Liu, J., Ren, H., Tang, T., Wang, J., Fang, J., Huang, C., Zheng, Z., & Qin, B. Y. (2023) · ACS Catalysis · doi:10.1021/acscatal.3c01363 · Cited by 12
Aryl Hydrocarbon Receptor as an Anticancer Target: An Overview of Ten Years Odyssey
Hanieh, H., Ismail, M. B., Alfwuaires, M. A., Ibrahim, H.-I. M., & Farhan, M. (2023) · Molecules · doi:10.3390/molecules28103978 · Cited by 14
Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment
Cheng, H., & Zheng, Y. (2024) · PeerJ · doi:10.7717/peerj.16825 · Cited by 13
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Stinson, J. A., Sheen, A. M., Lax, B. M., Yang, G. N., Duhamel, L., Santollani, L., Fink, E., Palmeri, J. R., & Wittrup, K. D. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0163 · Cited by 11
Novel ZIF-67-derived Co3O4 hollow nanocages as efficient nanozymes with intrinsic dual enzyme-mimicking activities for colorimetric sensing
Chi, J., Hu, J., Jin, R., Zhou, S., Wen, S., Jiang, Q., Ju, P., & Zhai, X. (2025) · Microchimica Acta · doi:10.1007/s00604-025-07112-1 · Cited by 11
Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number
Hawlina, S., Chowdhury, H. H., Smrkolj, T., & Zorec, R. (2022) · Biology Direct · doi:10.1186/s13062-022-00318-w · Cited by 12
Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencingPreprint
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.08.868828 · Cited by 11
Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming
Zhou, R., Li, Y., Li, G., Li, Y., Luo, L., Wang, B., & Wang, L. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02492-7 · Cited by 11
KYNU-related transcriptome profile and clinical outcome from 2994 breast tumors
Li, Y., Wang, M., Zhao, L., Chen, L., & Li, W. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17216 · Cited by 10
Uterine Commensal Peptostreptococcus Species Contribute to IDO1 Induction in Endometrial Cancer via Indoleacrylic Acid
Wang, Q., Liu, Y., Chen, W., Chen, S., Su, M., Zheng, Y., Liu, W., Li, L., Zeng, L., Shi, Q., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030573 · Cited by 10
SP94 engineered erythrocyte membrane enhanced the targeted delivery of biomimetic nanosuspension with IDO immunotherapy and chemotherapy in liver cancer
Raza, F., Jiang, L., Zhang, S., Zafar, H., Qiu, Y., Su, J., & Qiu, M. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.151709 · Cited by 10
Discovery of highly active kynureninases for cancer immunotherapy through protein language model
Eom, H., Park, S., Cho, K. S., Lee, J., Kim, H., Kim, S., Yang, J., Han, Y.-H., Lee, J., Seok, C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1245 · Cited by 10
Mechanistic conformational and substrate selectivity profiles emerging in the evolution of enzymes via parallel trajectories
Karamitros, C. S., Murray, K., Kumada, Y., Johnson, K. A., D’Arcy, S., & Georgiou, G. (2024) · Nature Communications · doi:10.1038/s41467-024-51133-y · Cited by 10
Self-citation
Mechanism of miR-760 Reversing Lung Cancer Immune Escape by Downregulating IDO1 and Eliminating Regulatory T Cells Based on Mathematical Biology
Ge, H., Wang, L., Chen, W., & Wang, L. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/2960773 · Cited by 10
Supramolecular Modulation of Tumor Microenvironment Through Host−Guest Recognition and Metal Coordination to Potentiate Cancer Chemoimmunotherapy
Wu, D. Q., Zhou, J., Zhang, Z., Cao, Y., Ping, K., Qi, S., Du, J., & Yu, G. (2025) · Advanced Science · doi:10.1002/advs.202408518 · Cited by 9
Novel tryptophan 2,3-dioxygenase-targeted ruthenium( ii )-indole complex activates immunotherapy in vitro and in vivo
Shen, Z., Guo, B., Dai, X., Liu, H., Ren, M., Wang, P., Zhang, Y., Xu, Y., Su, Z. G., Xue, X., et al. (2025) · Chemical Science · doi:10.1039/d5sc03778f · Cited by 9
Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies
Zhu, I., Piraner, D. I., & Roybal, K. T. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0962 · Cited by 9
Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters
Rajaiah, R., Pandey, K., Acharya, A., Ambikan, A. T., Kumar, N., Guda, R. S., Avedissian, S. N., Montaner, L. J., Cohen, S. M., Neogi, U., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110501 · Cited by 9
Conformational Dynamics Contribute to Substrate Selectivity and Catalysis in Human Kynureninase
Karamitros, C. S., Murray, K., Sugiyama, Y., Kumada, Y., Johnson, K. A., Georgiou, G., D’Arcy, S., & Stone, E. M. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00676 · Cited by 11
Self-citation
Adapting protein sequences for optimized therapeutic efficacy
Dellas, N., Liu, J., Botham, R. C., & Huisman, G. W. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.005 · Cited by 10
Reversing the immunosuppressive tumor microenvironment via “Kynurenine starvation therapy” for postsurgical triple-negative breast cancer treatment
Liu, Z., Yin, J., Qiu, T., Liu, A., Yu, Y., Yang, S., Liu, Z., & Li, Q. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113832 · Cited by 11
Dynamic remodeling of amino acid metabolism in tumor-associated macrophages: Fueling immunosuppression, reshaping tumor niches, and unlocking metabolic checkpoints
Ran, B., Xiao, L., Liu, Y., Zhang, C., Kong, L., Zhang, Y., Gu, X., Jiang, C., & Wu, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.025 · Cited by 10
IDO promotes the proliferation and invasion of prostate cancer cells through KYNU
Zhou, H., Wang, W., Liu, M., Xie, P., Deng, T., Peng, J., & Xu, C. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01316-y · Cited by 8
Blocking CTLA ‐4 promotes pressure overload‐induced heart failure via activating Th17 cells
Shang, A., Yu, C., Bi, X., Jiang, W., Zhao, M., Sun, Y., Guan, H., & Zhang, Z. (2024) · The FASEB Journal · doi:10.1096/fj.202400384r · Cited by 9
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance
Moon, P. K., Tran, S., & Minhas, P. S. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1784-8 · Cited by 8
Differential Gene Expression and Methylation Analysis of Melanoma in TCGA Database to Further Study the Expression Pattern of KYNU in Melanoma
Wang, M., Liu, M., Huang, Y., Wang, Z., Wang, Y., He, K., Bai, R., Ying, T., & Zheng, Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081209 · Cited by 8
Immune Cell Metabolism and Immuno-Oncology
Patel, C. H., & Powell, J. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-042605 · Cited by 9
Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cells
Giacomantonio, M., Vijayan, V. V., Nair, P. G., Pathak, G. P., Kennedy, B. E., Paulo, J. A., McMillen, T. S., Banerjee, A., Kumar, V., Sultonova, M., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117149 · Cited by 7
Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Gustafson, K. T., Mokhtari, N., Manalo, E. C., Mira, J. M., Gower, A., Yeh, Y., Vaidyanathan, M., Esener, S. C., & Fischer, J. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010143 · Cited by 7
Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies
Cox, J. R., Jennings, M. R., Lenahan, C., Manion, M., Courville, S., & Blazeck, J. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100394 · Cited by 7
Self-citation
Challenges of enzyme therapy: Why two players are better than one
Cuoghi, S., Caraffi, R., Anderlini, A., Baraldi, C., Enzo, E., Vandelli, M. A., Tosi, G., Ruozi, B., Duskey, J. T., & Ottonelli, I. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1979 · Cited by 9
Exploring the Surface: Sampling of Potential Skin Cancer Biomarkers Kynurenine and Tryptophan, Studied on 3D Melanocyte and Melanoma Models
Hasterok, S., Jankovskaja, S., Dahlström, R. M., Prgomet, Z., Ohlsson, L., Björklund, S., & Gustafsson, A. (2024) · Biomolecules · doi:10.3390/biom14070815 · Cited by 7
Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
Miljanic, M., Capasso, A., Triplett, T., Eckhardt, S. G., & Aung, K. L. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_1_20 · Cited by 7
Self-citation
Wumei Wan remodels the tumor immune microenvironment via the Ido1-KYN-AHR axis in AOM/DSS-induced colorectal cancer model
Zhang, Y., Yang, M.-J., Yang, S., Liu, Y., Jia, R., Zhang, X.-Y., Li, J., & Yan, S. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120371 · Cited by 6
Self-citation
Targeting T cell metabolism for immunotherapy
Gao, J., Liu, Y., Wei, J., Jiang, L., Mao, J., Chang, C.-H., & Wu, D. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0921-011r · Cited by 6
Amino Acid Metabolism in Bone Metastatic Disease
Edwards, D. N. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00797-4 · Cited by 6
Molecular Ensembles of Microbiotic Metabolites in Carcinogenesis
Shatova, O. P., Zabolotneva, A. A., & Shestopalov, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923070027 · Cited by 7
Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges
Tan, G. H., & Wong, C. C. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0037 · Cited by 6
Antineoplastic Enzyme as Drug Carrier with Activatable Catalytic Activity for Efficient Combined Therapy
Zhang, Y., Jiang, S., Lin, J., & Huang, P. (2022) · Angewandte Chemie · doi:10.1002/ange.202208583 · Cited by 6
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Aoki, K., Nishito, Y., Motoi, N., Arai, Y., Hiraoka, N., Shibata, T., Sonobe, Y., Kayukawa, Y., Hashimoto, E., Takahashi, M., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0415 · Cited by 6
Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment
Kaur, K., & Khatik, G. L. (2019) · Current Cancer Therapy Reviews · doi:10.2174/1573394715666190913184853 · Cited by 12
Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors
Ye, W., Xu, M., Gu, Y., & Ou, W. (2025) · ACS Omega · doi:10.1021/acsomega.5c06506 · Cited by 5
Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy
Yin, J., Yang, S., Liu, Z., Zhao, S., Sun, S., Liu, Z., & Li, Q. (2025) · Advanced Science · doi:10.1002/advs.202508107 · Cited by 6
Anthranilic Acid–G-Protein Coupled Receptor109A–Cytosolic Phospholipase A2–Myelin–Cognition Cascade: A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging
Oxenkrug, G. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413269 · Cited by 7
Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
Sawada, L., Vallinoto, A. C. R., & Costa, I. B. (2021) · Biomolecules · doi:10.3390/biom11121792 · Cited by 5
Enzymes in Nanomedicine for Anti-tumor Therapy
Zhou, T., Yuan, S., Qian, P., & Wu, Y. (2023) · Chemical Research in Chinese Universities · doi:10.1007/s40242-023-2349-1 · Cited by 5
Engineering CREB‐activated promoters for adenosine‐induced gene expression
Cox, J. R., Fox, A., Lenahan, C., Pivnik, L., Manion, M., & Blazeck, J. (2024) · Biotechnology Journal · doi:10.1002/biot.202300446 · Cited by 5
Self-citation
Inhibition of CTLA-4 accelerates atherosclerosis in hyperlipidemic mice by modulating the Th1/Th2 balance via the NF-κB signaling pathway
Zhao, M.-L., Chen, L., Jiang, W., Zhang, M., Guan, H., Hong, Z., Zhu, D., Shang, A., Yu, C., & Zhang, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37278 · Cited by 5
Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization
Griffith, B. D., Kadiyala, P., McGue, J. J., Sun, L., Kumar, A., Espinoza, C. E., Donahue, K. L., Iyer, M. K., Speyer, C. B., Nelson, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0377 · Cited by 5
Intra-tumor heterogeneity-resistant gene signature predicts prognosis and immune infiltration in breast cancer
Shen, H., Zheng, Q. L., Pan, J., Jin, Y., Zheng, X., Yuan, Q., Tan, D., Zhou, Q., Wang, J., & Sun, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1598858 · Cited by 4
Identification and characterization of rabbit scFv antibodies suitable for immuno-affinity separation of recombinant human kynureninase from Escherichia coli cell lysate
Sugimoto, K., Karamitros, C. S., Horiuchi, J., & Kumada, Y. (2024) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2023.12.016 · Cited by 4
Self-citation
Insights into Potent Therapeutical Antileukemic Agent L-glutaminase Enzyme Under Solid-state Fermentation: A Review
Durthi, C. P., Pola, M., Rajulapati, S. B., & Kola, A. K. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200421122147 · Cited by 4
Activity-based urinary biomarkers of response and resistance to checkpoint blockade immunotherapyPreprint
Mac, Q. D., Xu, C., Bowen, J. R., Sivakumar, A., Phuengkham, H., Su, F., Stentz, S. Z., Sim, H., Harris, A. M., Li, T. T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.10.420265 · Cited by 4
Global Trends in Research of Amino Acid Metabolism in T Lymphocytes in Recent 15 Years: A Bibliometric Analysis
蔡柳新, Yu, Y., Yu, Y., Meng, Y., Qiu, K., Niu, G., Wei, C., Chen, T., Wu, Y., Cai, X., et al. (2025) · Journal of Immunology Research · doi:10.1155/jimr/3393342 · Cited by 3
Non-invasive tape sampling of tryptophan and kynurenine in relation to phenylalanine and tyrosine from melanoma and adjacent non-lesional skin: A pilot study
Jankovskaja, S., Spégel, P., Nielsen, K., Björklund, S., Bost, J., Engblom, J., Christensen, G. B., Rogova, O., Morin, M., Hædersdal, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326457 · Cited by 3
Engineering Salmonella as an immune-metabolic modulator of the tumor microenvironment
Varsha, K. K., & Dwidar, M. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.01.010 · Cited by 3
Glucose and Lactate Cooperatively Deprived by a PD-1-Presenting Nanoemulsion for Potentiated Antitumor Immunotherapy
Zhang, Y., Chen, P., Wen, W., Qian, X., He, T., Fu, L., Lin, J., & Huang, P. (2026) · ACS Nano · doi:10.1021/acsnano.5c19115 · Cited by 3
Nano-immunomodulators for multi-pathway regulation of immunosuppressive microenvironment of colorectal cancer
Cao, X., Feng, N., Huang, Q., Zhang, Z., Zhao, Y., Li, Q., Xiao, J. Z., & Liu, Y. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161104 · Cited by 3
Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase
Karamitros, C. S., Somody, C. M., Agnello, G., & Rowlinson, S. W. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.793985 · Cited by 3
Self-citation
Metabolic profile analysis in hematological malignancies
Halicki, P., Cieśluk, K., & Piszcz, J. A. (2024) · Acta Haematologica Polonica · doi:10.5603/ahp.97467 · Cited by 2
Dual metabolism-disrupted nanoparticles for reprogramming the immune microenvironment to potentiate cuproptosis immunotherapy
Li, S., Ma, Z., Zhao, Y., Yan, J., Wang, X., Zhao, W., Jiao, J., Duan, X., & Zhang, G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101799 · Cited by 2
Tryptophan-kynurenine pathway: a possible new mechanism for the prevention and treatment of reproductive system-related diseases
Ou, Z., Xu, A., Su, H., Liu, Y., & Li, J. (2025) · PeerJ · doi:10.7717/peerj.20342 · Cited by 3
Bioresponsive immunomodulator nanocomplex for selective immunoengineering in metastatic lymph nodes
Deng, Y., Chen, M., Fang, T., Luo, T., Cao, X., & Chen, G. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2519625123 · Cited by 2
Metabolic rewiring of the tumor microenvironment: therapeutic intervention of multi-pathway adaptations to impede cancer metastasis
Kaushik, K., Singh, H., Jha, K., Singh, R. P., & Kaur, N. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1792455 · Cited by 2
Engineered microbes for cancer immunotherapy
Brennan, A. M., Sokolovska, A., Li, N., & Isabella, V. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00002-4 · Cited by 1
Suboptimal folic acid exposure rewires oncogenic metabolism and proteomics signatures to mediate human breast cancer malignancy
Huang, A., Huang, S.-Y., SHAH, P. M., Ku, W., Huang, K., Liu, Y., Su, C., & Huang, R.-F. S. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109000 · Cited by 3
Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs
Tseng, Y.-H., Lin, H.-P., Lin, S.-Y., Chen, B., Vo, T. N. N., Yang, S., Lin, Y., Prijovich, Z. M., Czosseck, A., Leu, Y.-L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.026 · Cited by 2
Immunomodulatory Synthetic Glycocluster Molecule Prevents Melanoma Growth In Vivo
Honkanen, M., Narvi, E., Ojala, V. K., Jokilammi, A., Rantakari, P., Kronqvist, P., Kähäri, V., Veräjänkorva, E., Kurppa, K. J., Rahkila, J., et al. (2024) · ChemBioChem · doi:10.1002/cbic.202400264 · Cited by 2
Enzymes and Their Clinical Applications
Singh, P. K., Tripathi, M., Garg, P., Singh, R. L., Pathak, N., Shukla, S., & Singh, P. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-4723-8_10 · Cited by 2
Is the immunogenicity of PD-1 blocking antibodies a confounding variable in murine studies?
Buss, L. A., Dachs, G. U., Goddard, L., Ang, A. D., Robinson, B. A., Currie, M. J., & Hock, B. D. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.04.003 · Cited by 2
Kynurenic acid as chronic pain biomarker for future cancer pain management
Waloejo, C. S., Rehatta, N. M., Andriyanto, L., Sulistiawan, S. S., Pudjirahardjo, W. J., Farhan, A. B., Kurniasari, H., & Chen, Y. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns5.11277 · Cited by 3
Medical Nanozymes for Therapeutics
Liu, Y., Yan, X., & Wei, H. (2023) · Micro/Nano technologies · doi:10.1007/978-981-16-8984-0_26 · Cited by 2
Indoleamine 2,3-dioxygenase 1-mediated immune suppressive status is positively associated with brain metastasis in patients with non-small cell lung cancer
Chen, W., Li, Y., Lee, V. H.-F., Xu, L., Ma, L., Ye, Z., Xu, W., Zhao, C., Zheng, D., Kiang, K. M. Y., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.12.004 · Cited by 1
Innate immune cells in oral squamous cell carcinoma: Characteristics and therapeutic potential
Jiang, Y., Cheng, J., Wu, J., Liu, O., & Bin, X. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189444 · Cited by 1
Enzymes reloaded: Nanotechnology's role in the next generation of cancer therapies
Gameel, M., elsayed, D. A., Shehab, W. S., Magdy, N., M.Al-Erian, A., Emwas, A.-H. M., Jaremko, M., & Elmansy, M. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102889 · Cited by 1
Engineered Clostridium butyricum: a promising application of synthetic biology in comprehensive health
Li, K., Kong, Y., & Chen, T. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02901-y · Cited by 1
Metabolic crosstalk between cancer and stromal cells: Implications for precision oncology
Yang, W., Ding, Y., & Tian, H. (2026) · Surgical Oncology · doi:10.1016/j.suronc.2026.102366 · Cited by 1
Self-Assembled Nanoparticles with Kynureninase-Fc Fusion Protein and Pheophorbide A for Photodynamic Immunometabolic Cancer Therapy
Zhang, C., Yang, A., Lin, H., Li, Z., & Lü, W. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17020094 · Cited by 1
Memory programming and new manufacturing paradigms in CAR-T cell therapy
Mohammadkhani, N., Ebrahimi, S., Mohammadi, M. H., Hartmann, T. N., & Poorebrahim, M. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01015-w · Cited by 1
Metabolic reprogramming of CAR-T cells: a multi-pronged strategy to conquer the immunosuppressive tumor microenvironment
Zheng, Z., Chen, Z., Zhang, Z., & Zheng, Z. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02864-6 · Cited by 1
Long noncoding RNA AFAP1-AS1 aggravates immunotherapy resistance in NSCLC by enhancing JAK2 and TYK2 translation
Zhang, Y., Ouyang, J., Yan, Q., Ge, J., Wu, P., Wang, D., Li, L., Zhang, J., Zhong, Y., Yang, L., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.04.055 · Cited by 1
Kynurenine pathway impact on immune evasion and inflammation in acute myeloid leukemia
Wawrzak-Pienkowska, K., Golonko, A., Ignatiuk, D., Swidnicka-Siergiejko, A. K., Pienkowski, T., & Kurek, K. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124474 · Cited by 1
Overcoming immunotherapy resistance in extensive-stage small cell lung cancer: Insights into mechanisms and therapeutic opportunities
Guan, R., Zhang, C., Zhang, J., Du, S., Wang, H., Zhang, Y., Abdi, A. A. M., & Wang, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105411 · Cited by 1
Enzyme-based nanomedicine for tumor microenvironment modulation in cancer therapy
Ta, Y. N., Wang, S.-N., & Chen, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115101 · Cited by 2
Domino Effect of the Kynurenine Pathway: Systemic Homeostasis, Metabolic Crosstalk, and Therapeutic Potential
Ma, P.-J., Man, Y., Shen, F.-Q., Li, M., Wang, H., Ren, F.-L., Ye, J.-Y., Pan, Y. P., & Wang, Y. (2026) · Comprehensive physiology · doi:10.1002/cph4.70207 · Cited by 1
Tryptophan metabolism in tumor immune escape: mechanisms, cellular crosstalk, and therapeutic opportunities
Chen, J., Wang, X. L., Gong, M., Wang, Y., & Yu, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1878140 · Cited by 2
Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
Wang, M.-X., Gao, S.-Y., Yang, F., Fan, R., Yang, Q.-N., Zhang, T., Qian, N., & Guang-hai, D. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i9.729 · Cited by 1
Comparative Ability of Various Immunosuppressants as Adjuvants on the Activity of T1D Vaccine
Wang, X., Xie, M., Li, T., Shi, J., Wu, M., Zhang, S., Sun, J., & Hu, Y. (2024) · Vaccines · doi:10.3390/vaccines12101117 · Cited by 1
Zinc dampens anti-tumour immunity by promoting Foxp3+ regulatory T cellsPreprint
Awasthi, A., Sugandha, N., Dalal, R., & Rizvi, Z. A. (2023) · Research Square · doi:10.21203/rs.3.rs-3344750/v1 · Cited by 1
The immune system: A common link mediating exercise effects on the tumour microenvironment and skeletal muscle mitochondria?
Buss, L. A. (2020) · Otago University Research Archive (University of Otago)
Medical Nanozymes for Therapeutics
Liu, Y., Yan, X., & Wei, H. (2022) · Micro/Nano technologies · doi:10.1007/978-981-13-9374-7_26-1
Genetic and Epigenetic Dysregulation in Environmental Disease
Ramos, K. S., Hassanin, A. A. I., & Wang, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00034-4
Additional file 1 of Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers
Zhang, Y., Mao, Q., Xia, Q., Cheng, J., Huang, Z., Li, Y., Chen, P., Yang, J., Fan, X., Liang, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16821779
Additional file 2 of Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers
Zhang, Y., Mao, Q., Xia, Q., Cheng, J., Huang, Z., Li, Y., Chen, P., Yang, J., Fan, X., Liang, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16821782
Molecular orchestra of microbiotic metabolites in the scenario of carcinogenesis
Shatova, O. P., Zabolotneva, A. A., & Shestopalov, A. V. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523070023
Development of smart optical nanoagents for cancer immunotheranostics
Xu, C. (2024) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/179290
Modulating T cell metabolism to improve T cell therapy
Li, Y., Hung, S.-H., Singh, S., & Yee, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00008-1
Electrochemical Analysis and Inhibition Assay of Immune-Modulating Enzyme, Indoleamine 2,3-Dioxygenase
Mie, Y., Mikami, C., Yasutake, Y., Shigemura, Y., Yamashita, T., & Tsujino, H. (2025) · Pharmaceuticals · doi:10.3390/ph18030352
The Effect of Kynureninase on Cancer Treatment
Chen, C. (2025) · MedScien · doi:10.61173/dn3jy275
Additional file 1 of Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification
Huai, M., Wang, Y., Li, J., Pan, J., Sun, F. Z., Zhang, F., Zhang, Y., & Xu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26721432

Authors: Triplett, T. A., Garrison, K. C., Marshall, N., Donkor, M., Blazeck, J., Lamb, C., Qerqez, A., Dekker, J. D., Tanno, Y., Lu, W.-C., Karamitros, C. S., Ford, K., Tan, B., Zhang, X. M., McGovern, K., Coma, S., Kumada, Y., Yamany, M. S., Sentandreu, E., Fromm, G., Tiziani, S., Schreiber, T. H., Manfredi, M., Ehrlich, L. I. R., Stone, E., & Georgiou, G.
Affiliations: The University of Texas at Austin (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Kyoto Institute of Technology (JP)
Heat Biologics (United States) (US)
Corresponding author: Stone, Everett
Georgiou, George
ORCID: Triplett, Todd A
Marshall, Nicholas
Blazeck, John
Lamb, Candice
Qerqez, Ahlam
Dekker, Joseph D
Tanno, Yuri
Karamitros, Christos S
Ford, Kyle
Tan, Bing
Zhang, Xiaoyan M
McGovern, Karen
Kumada, Yoichi
Sentandreu, Enrique
Fromm, George
Tiziani, Stefano
Schreiber, Taylor H
Manfredi, Mark
Ehrlich, Lauren I R
Stone, Everett
Georgiou, George
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2018-07-16
Volume: 36
Issue: 8
Pages: 758-764
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4180
PMC: PMC6078800
OpenAlex: W2883967352
Cited by: 321
References: 40
Citations by year: 2026: 39 · 2025: 40 · 2024: 52 · 2023: 43 · 2022: 49 · 2021: 44 · 2020: 29 · 2019: 22 · 2018: 3
FWCI: 9.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA189623)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords: indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, kynurenine, kynureninase, tumor immunosuppression, tryptophan catabolism, tumor microenvironment, CD8+ T cells, immune checkpoint inhibitors, cancer vaccines, melanoma, breast cancer, colon cancer, enzyme therapy
MeSH terms: Adjuvants, Immunologic, Animals, Humans, Hydrolases, Kynurenine, Neoplasms, Cancer Vaccines, Cell Line, Tumor, Indoleamine-Pyrrole 2,3,-Dioxygenase, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks